Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARGOT: Neoadjuvant Margetuximab vs Trastuzumab in HER2+ Breast Cancer
NCT04425018Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2020
- Primary completion
- Oct 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of margetuximab in breast cancer (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Pathologic Complete Response at 12 weeks. Started Jul 2020; status: active, not recruiting.
02
Drugs
margetuximab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04425018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04425018.